Healthcare May 11, 2022 02:46 PM (GMT+8) · EqualOcean
On May 11, yiouda health learned that the exclusive report of foreign media endpts news said that green valley pharmaceutical was the original new drug for the treatment of Alzheimer's disease (AD) ® The international phase III clinical trial of (ganlute sodium capsule; Code: gv-971) has been stopped, and five clinical trial centers have confirmed the news to endpts news. Four of them said they had stopped the experiment because of supply chain problems, but another claimed that it had nothing to do with the supply chain. Eric Reiman, a former scientific consultant of Green Valley pharmaceutical, said he was informed that the trial had been stopped due to "unexpected financial challenges related to the covid-19 pandemic in China". "Based on the information shared with us, the consultants were not informed of any safety issues related to treatment," he said in an email to endpoints. Eric Reiman is also the executive director of banner Alzheimer's Institute, according to ClinicalTrials Gov, the Institute is listed as one of nine issues ® One of the clinical trial sites of the international multicenter phase III trial. The news came as Bojian and Weicai had just completed the second rolling submission of their new ad drug aduhelm, and Lilly was also preparing the application of donanemab.

This text is a result of machine translation.